Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613618 | 0.90 | TRPV1 (0.58) | TRPV1MEN1KMT2A | |
| SCHEMBL13613590 | 0.85 | TRPV1 (0.60) | TRPV1MEN1KMT2A | |
| SCHEMBL4333852 | 0.85 | TRPV1 (0.71) | TRPV1EPHX2OPRM1MEN1KMT2A | |
| SCHEMBL13613591 | 0.83 | TRPV1 (0.59) | TRPV1MEN1KMT2A | |
| SCHEMBL4332079 | 0.83 | TRPV1 (0.71) | TRPV1EPHX2OPRM1MEN1KMT2A | |
| SCHEMBL13613701 | 0.81 | TRPV1 (0.65) | TRPV1EPHX2BRAF | |
| SCHEMBL2734361 | 0.80 | TRPV1 (0.67) | TRPV1OPRM1MEN1KMT2A | |
| SCHEMBL2734505 | 0.80 | TRPV1 (0.56) | TRPV1MEN1KMT2A | |
| SCHEMBL208537 | 0.79 | TRPV1 (0.66) | TRPV1OPRM1TRPM8 | |
| SCHEMBL2734506 | 0.79 | TRPV1 (0.55) | TRPV1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |